HIV associated nephropathy natural history, complications and prognosis: Difference between revisions
No edit summary |
|||
Line 2: | Line 2: | ||
{{HIV associated nephropathy}} | {{HIV associated nephropathy}} | ||
{{CMG}}{{APM}};{{AE}}{{KW}} | {{CMG}}{{APM}};{{AE}}{{KW}} | ||
==Overview== | |||
==Natural History== | ==Natural History== |
Revision as of 12:08, 20 December 2016
HIV associated nephropathy Microchapters |
Differentiating HIV associated nephropathy from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
HIV associated nephropathy natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of HIV associated nephropathy natural history, complications and prognosis |
FDA on HIV associated nephropathy natural history, complications and prognosis |
CDC on HIV associated nephropathy natural history, complications and prognosis |
HIV associated nephropathy natural history, complications and prognosis in the news |
Blogs on HIV associated nephropathy natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2];Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]
Overview
Natural History
If left untreated, HIV-associated nephropathy will progress to end-stage renal disease in a few weeks to months.
Complications
Possible complications that are associated with HIV-associated nephropathy include:
Prognosis
In the past, before the advent of HAART therapy, the prognosis of HIV-associated nephropathy was fatal. The mortality rate during this time was 100% within 6 months. Today, the prognosis with the availability of HAART therapy still remains grim, however, its availability has increased renal survival rate.
The following are favorable prognostic factors:
- Patients on HAART therapy
- Patients with low-grade proteinuria
- Patients who have a suppressed HIV-1 viral load
- Patients who express a normal renal echogenicity
- Patients with CD4 levels that between 200 and 500 cells/mm3
- Patients who have higher estimated glomerular filtration rates
The following are poor prognostics factors:
- Patients not receiving HAART therapy
- Patients with high-grade proteinuria
- Patients who have under suppressed HIV-1 viral load
- Patients who express a large renal echogenicity
- Patients who have CD4 levels that are below 200 cells/mm3
- Patients who have lower estimated glomerular filtration rates
The current first and second year survival rate of HIV-associated nephropathy is estimated to be around 63% and 43% respectively, with the use of HAART therapy.